>
Switch to:

Allergy Therapeutics Sloan Ratio %

: -3.40% (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Allergy Therapeutics's Sloan Ratio for the quarter that ended in Jun. 2021 was -3.40%.

As of Jun. 2021, Allergy Therapeutics has a Sloan Ratio of -3.40%, indicating the company is in the safe zone and there is no funny business with accruals.


Allergy Therapeutics Sloan Ratio % Historical Data

The historical data trend for Allergy Therapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Sloan Ratio %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -2.41 1.78 -3.38 -3.26

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Sloan Ratio % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 -1.30 -3.29 -1.39 -3.40

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Sloan Ratio % Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Sloan Ratio % falls into.



Allergy Therapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Allergy Therapeutics's Sloan Ratio for the fiscal year that ended in Jun. 2021 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2021 )-Cash Flow from Operations (A: Jun. 2021 )
-Cash Flow from Investing (A: Jun. 2021 ))/Total Assets (A: Jun. 2021 )
=(4.0476858345021-11.779803646564
--3.7012622720898)/123.54698457223
=-3.26%

Allergy Therapeutics's Sloan Ratio for the quarter that ended in Jun. 2021 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM})
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2021 )
=(3.174672744273-11.03255025713
--3.6569658719028)/123.54698457223
=-3.40%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. Allergy Therapeutics's Net Income for the trailing twelve months (TTM) ended in Jun. 2021 was 20.079301075269 (Dec. 2020 ) + -16.904628330996 (Jun. 2021 ) = $3.2 Mil.
Allergy Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2021 was 17.186827956989 (Dec. 2020 ) + -6.1542776998597 (Jun. 2021 ) = $11.0 Mil.
Allergy Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2021 was -1.0188172043011 (Dec. 2020 ) + -2.6381486676017 (Jun. 2021 ) = $-3.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2021, Allergy Therapeutics has a Sloan Ratio of -3.40%, indicating the company is in the safe zone and there is no funny business with accruals.


Allergy Therapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)